A Manhattan Project for Bioterrorism

A new "Manhattan Project" to combat bioterrorism has been proposed by US Senate Majority Leader Bill Frist and many others.

Written byNorman Anderson
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Courtesy of Viral Defense Foundation

Norman G. Anderson (right) is president and founder of the Viral Defense Foundation http://viraldefense.org, and N. Leigh Anderson (left) is CEO of the Plasma Proteome Institute. Previously they jointly founded the Molecular Anatomy Program at the Argonne National Laboratory, and a biotechnology company, Large Scale Biology.

A new "Manhattan Project" to combat bioterrorism has been proposed by US Senate Majority Leader Bill Frist and many others. But what would such a project look like? And is it a good idea? For some answers, it is worth reviewing the history of the original Manhattan Project.

We have between us spent almost 38 years in national laboratories at Oak Ridge, Tenn., and Argonne, Ill., which were both derived from the Manhattan Project. The Project had a clear central objective, a decisive test for success or failure, leadership by technically competent hands-on scientists, access to all discoverable intellectual ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies